Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Lushang Freda Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:
SHSE:600223'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.34 Med: 11.03 Max: 37.88
Current: 0.38
During the past 13 years, the highest Debt-to-EBITDA Ratio of Lushang Freda Pharmaceutical Co was 37.88. The lowest was 0.34. And the median was 11.03.
SHSE:600223's Debt-to-EBITDA is ranked better than 90.99% of 1265
companies
in the Real Estate industry
Industry Median: 5.51
vs SHSE:600223: 0.38
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Lushang Freda Pharmaceutical Co Debt-to-EBITDA Related Terms
Lushang Freda Pharmaceutical Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co Debt-to-EBITDA Chart
Lushang Freda Pharmaceutical Co Debt-to-EBITDA Competitor Comparison
For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lushang Freda Pharmaceutical Co Debt-to-EBITDA vs Real Estate Industry
For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lushang Freda Pharmaceutical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Lushang Freda Pharmaceutical Co (SHSE:600223) has a Debt-to-EBITDA of 0.33 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lushang Freda Pharmaceutical Co. This is 97% below median its historical median of 11.03. Over the past decade, Lushang Freda Pharmaceutical Co's Debt-to-EBITDA has ranged from 0.34 to 37.88. According to the industry distribution chart, Lushang Freda Pharmaceutical Co ranks #114 out of 1265 companies in the Real Estate industry, placing it in the top 9%.
Is Lushang Freda Pharmaceutical Co's Debt-to-EBITDA too high?
Lushang Freda Pharmaceutical Co's current Debt-to-EBITDA of 0.33 is 97% below median its 10-year median of 11.03. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 37.88. The Real Estate industry median Debt-to-EBITDA is 5.51. Lushang Freda Pharmaceutical Co's value of 0.33 is 94% below this industry median. Based on the distribution chart, Lushang Freda Pharmaceutical Co ranks #114 out of 1265 companies in the Real Estate industry, which is in the top quartile — a strong position relative to peers. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's Debt-to-EBITDA compare to competitors?
According to the Real Estate industry distribution chart, Lushang Freda Pharmaceutical Co ranks #114 out of 1265 companies for Debt-to-EBITDA. This places Lushang Freda Pharmaceutical Co in the top 9% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 5.51. Lushang Freda Pharmaceutical Co's value of 0.33 is 94% below this benchmark. Historically, Lushang Freda Pharmaceutical Co's own Debt-to-EBITDA has ranged from 0.34 to 37.88 over the past decade. While the company's 10-year median is 11.03 vs. the industry median of 5.51, Lushang Freda Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Real Estate company?
The median Debt-to-EBITDA among Real Estate companies is 5.51, based on 1,265 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lushang Freda Pharmaceutical Co's current Debt-to-EBITDA of 0.33 is 94% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lushang Freda Pharmaceutical Co. For the Real Estate industry, the median Debt-to-EBITDA is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lushang Freda Pharmaceutical Co's current Debt-to-EBITDA is 0.33, which is 97% below median its own 10-year median of 11.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.84, compared to a current price of ¥5.52 — trading 19.3% below its estimated fair value. The current Debt-to-EBITDA is 0.33, which is 97% below median its 10-year median of 11.03 and 94% below the Real Estate industry median of 5.51. Lushang Freda Pharmaceutical Co's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current Debt-to-EBITDA is 0.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥5.52 is trading 19.3% below its estimated GF Value™ of ¥6.84.
GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600223:
Debt-to-EBITDA: 0.33 (97% below median its 10-year median of 11.03)
GF Value™: ¥6.84 vs. price of ¥5.52 (19.3% below fair value)
Industry Position: 94% below the Real Estate median (#114 of 1265)
No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
72GF Score
Get the complete analysis for SHSE:600223
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600223 has been successfully added to your 
